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ABSTRACT 
 
Organogels can be prepared by immobilizing an organic phase into a three-
dimensional network coming from the self-assembly of a low molecular weight 
gelator molecule. In this work, an injectable subcutaneous organogel system based on 
safflower oil and a modified-tyrosine organogelator was evaluated in vivo for the 
delivery of rivastigmine, an acetylcholinesterase (AChE) inhibitor used in the 
treatment of Alzheimer’s disease. Different implant formulations were injected and 
the plasmatic drug concentration was assayed for up to 35 days. In parallel, the 
inhibition of AChE in different brain sections and the biocompatibility of the implants 
were monitored. The pharmacokinetic profiles were found to be influenced by the gel 
composition, injected dose and volume of the implant. The sustained delivery of 
rivastigmine was accompanied by a significant prolonged inhibition of AChE in the 
hippocampus, a brain structure involved in memory. The implant induced only a 
minimal to mild chronic inflammation and fibrosis, which was comparable to 
poly(D,L-lactide-co-glycolide) in situ-forming implants. These findings suggest that 
tyrosine-based organogels could represent an alternative approach to current 
formulations for the sustained delivery of cholinesterase inhibitors. 
*Abstract
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INTRODUCTION 
 
An organogel is a non-glassy thermoreversible semi-solid system composed of an 
organic liquid phase entrapped in a three-dimensionally cross-linked network. The 
liquid phase can be an organic solvent or an oil, whereas the structuring network is 
formed by self-assembled low molecular weight or polymeric organogelator 
molecules. Organogels have been investigated in fields as diverse as molecular 
photonics [1], art conservation [2] and food industry [3]. In the area of pharmaceutical 
sciences, organogels have only received a marked interest in recent years [4-6]. They 
have been tested with more or less success for the administration of 
inflammatory/analgesic drugs [7-9], cardiovascular drugs [4], antipsychotics [10] as 
well as nucleic acids [11] and peptides [12] by the transdermal, rectal, oral and buccal 
routes. In drug delivery, organogels are generally prepared using biocompatible and 
safe gelating molecules such as lecithin [8,13-15], sorbitan monostearate (SMS) 
[4,12,16] and amino acid derivatives [17]. A promising avenue for organogels lies in 
their use as depot formulations following parenteral extravascular injection. 
Compared to polymeric hydrogels, organogels have the ability to better retain low 
molecular weight polar compounds in their matrix [18]. Also, as opposed to implants 
based on lactic acid copolymers [19], their inner structure does not acidify upon 
degradation, which could be an advantage for the formulation of acid-sensitive 
pharmacological agents. Injectable organogels based on SMS or glyceryl esters of 
fatty acids have been successfully employed as vaccine adjuvants [16] and depot 
formulations for contraceptive steroids [20].  
 
Over the past 6 years, we have been studying the ability of hydrophobized amino 
acids such as L-alanine [21] and L-tyrosine [22] to self-assemble in vegetable oils and 
form semi-solid/solid systems at body temperature. In order to partially inhibit 
gelation at room temperature and allow the injection of the formulation, a small 
amount of N-methyl pyrrolidone (NMP), a biocompatible and water-soluble 
hydrophilic organic solvent [23], is added to the oil/organogelators/drug mixture. Gel 
formation occurs after the subcutaneous (s.c.) injection of the formulation upon 
diffusion of the gelation inhibitor NMP into the surrounding tissues. The implants 
based on N-stearoyl L-alanine methyl ester (SAM) (in safflower oil) were found to be 
*Manuscript
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well tolerated in rats [24] and effective to deliver some drugs in a prolonged manner. 
The incorporation of leuprolide, an inhibitor of testosterone secretion, into these 
implants resulted in an efficient chemical castration of male rats for up to 50 days 
[25]. More recently, the same SAM organogels were assessed for the parenteral 
sustained delivery of rivastigmine, an AChE inhibitor prescribed to patients suffering 
from mild to moderate Alzheimer’s disease [26]. Rivastigmine is currently marketed 
as oral solution, capsules or transdermal patch requiring daily dosing [27]. It is 
therefore of potential interest to develop a sustained release formulation that would 
only require a few injections per year. In vivo, the SAM gels were found to release the 
rivastigmine during only 10 days [25]. Moreover, the analytical assay involved the 
use of tritium-labelled rivastigmine and therefore the plasma concentration could have 
been partly biased by radiolabeled metabolites or degradation products. 
 
Recently, we discovered that organogels prepared with L-tyrosine derivatives yielded 
implants with better mechanical properties, higher gel-sol transition temperatures and 
lower burst release in vitro [22]. In the present study, the sustained release properties 
of such implants following s.c. injections were investigated for the first time in rats. 
The effects of gel composition (L-alanine vs. L-tyrosine), dose (15 vs. 25 mg.kg-1) and 
implant volume (300 vs. 500 µL) on rivastigmine plasma concentrations were 
evaluated by LC/MS/MS. In addition, the AChE activity of the formulation in 
different sections of the brain as well as the biocompatibility of the rivastigmine-
loaded implants were assessed in rats (Figure 1). 
 
 
MATERIALS AND METHODS 
 
Materials 
SAM and N-behenoyl L-tyrosine methyl ester (BTM) were synthesized as previously 
described [22]. NMP and 7-(β hydroxyethyl) theophyllin were purchased from Sigma-
Aldrich Canada Ltd. (Oakville, ON, Canada) and used as supplied. Super-refined 
safflower oil (fatty acid composition of the triglycerides: 72.0% linoleic acid (C18:2), 
16.6% oleic acid (C18:1), 7.4% palmitic acid (C16:0), 2.5% stearic acid (C18:0), and 
1.5% v/v others) was kindly provided by Croda Inc. (Toronto, ON, Canada). 
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Rivastigmine hydrogen tartrate was purchased from LGM Pharmaceuticals Inc. (Boca 
Raton, FL). Eligard® (22.5 mg, 3-months) was from Sanofi Aventis (Laval, QC, 
Canada). 
 
Formulation preparation   
BTM, SAM and rivastigmine were sterilized by γ-irradiation at 25 kGy using a 60Co 
source (Nordion Inc., Laval, QC, Canada). Stability after sterilization of the 
organogelators and drug was confirmed by 1H-NMR. The chemical shifts (ppm) of the 
organogelator in CDCl3 obtained with a Bruker ARX-400 spectrometer (400 MHz, 
Bruker, Milton, ON, Canada) before and after γ-irradiation did not change: BTM: 0.9 
(triplet t, 3 H), 1.2 (multiplet m, 16 H), 1.6 (quintuplet q, 2 H), 2.2 (t, 2 H), 3.0 (m, 2 
H), 3.7 (singlet s, 3 H), 4.9 (doublet of triplets dt, 1 H), 5.5 (s, 1 H), 5.8 (doublet d, 1 
H), 6.7 – 7.0 (m, 4 H); SAM: 0.9 (t, 3H), 1.2 (m, 32H), 1.4 (d, 3H), 1.6 (q, 2H), 2.2 (t, 
2H), 3.7 (s, 3H), 4.6 (q, 1H), 6.0 (d, 1H). Safflower oil and NMP were sterilized on 
0.2-µm polytetrafluoroethylene filters. All formulations were prepared under aseptic 
conditions. Organogelator (5% w/w) and safflower oil were weighed into a 
polyethylene flask, mixed and heated to 90°C. Once the organogelator was dissolved, 
the temperature was decreased to 80°C and rivastigmine powder was physically 
dispersed in the oily solution by magnetic stirring. NMP (3% w/w of oil) was then 
added and syringes (20G1-gauge needle) were immediately filled with the hot 
dispersion (400 or 600 µL) and placed on ice for 30 min. Control formulations 
included an oil/NMP/rivastigmine solution devoid of organogelator (pharmacokinetic 
study, PK), a saline solution of rivastigmine (0.045% w/v) (enzymatic titration study, 
ET) and gel formulation devoid of rivastigmine (biocompatibility study, BC). Table I 
lists the composition of each formulation and controls tested in vivo. 
 
For drug content analysis a 100-µL sample from each syringe was dissolved in 1 mL 
of NMP, mixed with 9 mL of phosphate-buffered saline (PBS) (104 mM NaH2PO4, 36 
mM NaCl, 0.1% w/v NaN3, pH 7.4), and assayed by HPLC. A Gilson Model 302 
HPLC system (Gilson, Middletown, WI) equipped with a Gilson 234 autoinjector, a 
Gilson 106 pump and a Gilson 151 dual-wavelength UV-detector was employed. An 
Altima guard column (C18, 4.6 × 7.5 mm, 5 µm; Mandel Scientific Company Inc., 
Guelph, ON, Canada) was placed upstream of the XTerra (RP-18, 4.6 × 250 mm, 5 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4 
 
µm) analytical column (Waters, Mississauga, ON, Canada). The mobile phase 
consisted of water/acetonitrile (78/22 v/v) with 0.1% (v/v) trifluoroacetic acid. The 
flow rate was set at 1 mL.min-1. Injection volume and detection wavelength were 20 
µL and 210 nm, respectively. Each formulation was analyzed in triplicate. Table I 
displays measured rivastigmine concentrations and injected doses for individual 
formulations.  
 
Pharmacokinetic study 
All experimental procedures involving animals were conducted following a protocol 
approved by the Animal Care Committee of the University of Montreal and complied 
with The Guide for the Care and Use of Laboratory Animals (NIH Publication no. 85-
23, revised 1996). Male Sprague Dawley rats (300-325 g; Charles Rivers Inc., St-
Constant, QC, Canada) were housed for 1 week under controlled conditions (12-h 
light/dark schedule, 24°C) prior to experiments. Tap water was provided ad libitum 
while chow was controlled at 5 g/day/100 g rat body weight. Rats were randomly 
divided into 5 groups (n=8/group) and received a single s.c. injection of the 
appropriate formulation (Table 1, PK study) in the higher dorsal area under isoflurane 
anaesthesia. After the injection, the needle was held in place for 10 s to prevent the 
semi-solid implant from leaking out from the injection site. The exact amount of 
injected formulation was obtained by weighing the syringes before and after injection. 
Blood samples (400-450 µL) were periodically collected from the subclavian vein 
under isoflurane anaesthesia into EDTA-K2 vials. Blood samples were centrifuged (15 
min, 1600 g, 4°C) to collect plasma. The latter (200 µL) was mixed with 20 µL of 
internal standard (IS) solution (7-(β hydroxyethyl) theophyllin, 4 µg.mL-1 in water) 
and 400 µL of methanol. The mixture was vortexed and centrifuged (20 min, 8000 g, 
25°C). Three hundred µL of supernatant was added to 500 µL of water before 
quantification of the rivastigmine concentration by LC/MS/MS (see below). The final 
composition in water/methanol was 75/25 (v/v) and the IS concentration was 48.4 
ng.mL-1. For the calibration curve, the rivastigmine concentrations spanned from 0.1 
to 500 ng.mL-1. 
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LC/MS/MS method 
Separations were performed on a Surveyor LC system coupled to a Quantum Ultra 
AM triple quadrupole mass spectrometer (Thermo Fisher, San Jose, CA). The 
chromatographic column was a Luna C18(2), 50 x 3.0 mm, 2.5 µm particle size 
(Phenomenex, Torrance, CA) operating at 0.2 mL.min-1. A water/acetonitrile linear 
gradient, containing 0.1% (v/v) formic acid, was used for elution. Separation was 
performed by increasing the acetonitrile concentration from 10 to 50% over 3 min. 
From 3 to 4 min, 90% acetonitrile was delivered through the column followed by an 
equilibration step with the starting mobile phase for a total run time of 8 min.  Positive 
ions were generated using a heated electrospray ionization source and mass spectra 
were acquired over two different scan events. In the first scan event, set up in selected 
reaction monitoring mode, the transition 251.3→206.3 was acquired for rivastigmine 
and 225.3→181.0 was acquired for the IS. The collision energies used were 14 and 18 
V and the Tune Lens were set to 90 and 75 for rivastigmine and the IS respectively. In 
the second scan event, set up in scan mode, mass spectra were acquired from m/z 100 
to 1000. The electrospray voltage was set at 3300 V and the capillary temperature at 
350oC. For the first 1.6 min, the chromatographic flow was diverted to waste in order 
to prevent residual salts or un-retained small molecules from plasma from entering the 
mass spectrometer. Useful LC-MS data was acquired from 1.6 to 4.5 min after which 
the flow was directed once again to waste in order to prevent residual plasma proteins 
from contaminating the mass spectrometer. The dynamic range of rivastigmine 
quantitation was evaluated using twenty calibration solutions with concentrations 
ranging from 0.1 to 500 ng.mL-1. A linear response with a correlation coefficient r2 of 
0.9964 was obtained for concentrations up to 350 ng.mL-1. The lower limit of 
quantitation of this method was 0.1 ng.mL-1.  
 
In vivo titration of AChE activity 
Rats were randomly divided into 3 groups (Table 1, ET study), which were sacrificed 
at different time points (n=8 per time point per group) and were given the 
rivastigmine formulation (Table I) by s.c. injection. Rats receiving the gel formulation 
were injected only once with 15 or 25 mg/kg rivastigmine whereas the control treated 
animals were given a daily dose of 1.5 mg/kg for 10 days (total injected dose: 15 
mg/kg). Three non-treated control groups were used for baseline value assessment 
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(Day 0). About 30 min prior to decapitation, rats received an intra-peritoneal injection 
of acepromazine (0.05 mg.kg-1). After decapitation, the brain was dissected and the 
following brain structures were extracted on ice: frontal, temporal and parietal 
cortices, striatum, and hippocampus. They were frozen immediately in 2-
methylbutane on dry ice and stored at -80°C. For analysis, homogenates of the 
different brain structures were prepared on ice in 25 mM Na/K/PO4 buffer (pH 7.4) 
using potter-elvehjem tissue grinders (Wheaton Science Products, Millville, NJ) and 
teflon pestles (Kontes Glass Co., Vineland, NJ). The protein concentration of each 
homogenate was assayed with a colorimetric test using the bicinchoninic acid (BCA) 
protein assay kit (Pierce, Rockford, IL) according to the supplier’s instructions. 
 
The AChE activity was evaluated with a photometric test based on Ellman et al.’s 
method [28]. This method relies on the production of thiocholine after 
acetylthiocholine hydrolysis. Thiol groups of thiocholine then react with 5,5’-
dithiobis[2-nitrobenzoate] (DTNB) to form 5-thio(2-nitrobenzoic acid) (yellow color). 
Homogenate samples, 25 mM Na/K/PO4 (pH 7.4) buffer and 5 mM acetylthiocholine 
were added in a 96-well plate. The plate was incubated at room temperature and under 
stirring during 30 min, followed by the addition of 500 µL DTNB solution composed 
of 125 mM of DTNB in ethanol/H2O/100 mM Na/K/PO4 buffer (pH 7.4) (48/32/20  
v/v/v). The optical density (OD) was immediately measured at 411 nm. The AChE 
activity (mmolthiocholine.mg-1protein.min-1) was calculated as: 
tml
OD
activityAChE
protein ..ε
=  
with εl = 13.6 mmol-1, mprotein being the protein amount measured by the BCA method 
(mg) and t = 30 min. Results were reported in %AChE activity, relative to the 
baseline activity. 
 
Biocompatibility study 
Rats were randomly divided into 2 groups (gels with or without rivastigmine) (Table 
1, BC study), which were sacrificed at different time points (n=3 per time point per 
group). The data were compared to 2 control groups: one group of rats did not receive 
any formulation (negative control) while the other group was given the Eligard® 
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formulation (in situ forming implant consisting of leuprolide, poly(D,L-lactide-co-
glycolide) (PLGA) and NMP). Rats were sacrificed by carbon dioxide asphyxia. 
Tissues adjacent to the injection site and the remaining implants were collected and 
fixed with 10% neutral-buffered formalin. All samples were processed and embedded 
in paraffin. Glass slides with 4-µm tissue sections were prepared using a Leica 2155 
microtome (Leica Microsystems Inc., Richmond Hill, ON, Canada). Slides of each 
implant were stained according to a hematoxylin-phloxin-safran (HPS) standard 
procedure, using hematoxylin (nucleus coloration) and phloxin (cytoplasmic 
coloration) for cellularity and cell number, and safran for collagen deposition and 
fibrous tissue formation [29]. The local inflammatory response was assessed by 
histological evaluation of the surrounding tissue for signs of acute inflammation 
(neutrophils and eosinophils) and chronic inflammation (histocytes, plasmocytes, 
lymphocytes, multinucleated giant cells, fibroblasts, neoangiogenesis, and collagen 
deposition) [30]. The intensity of the response was graded on a scale from absent, 
minimal, mild, moderate, and significant to severe, depending on the number of cells 
and general appearance of the tissue. 
 
Statistical analysis 
For AChE titration, normal distribution was verified for each data set. Significant 
differences between means of %AChE activity were analyzed by one-way analysis of 
variance (ANOVA), followed by Tukey-Kramer’s post-hoc test for pairwise 
comparisons. Differences were considered statistically significant for p < 0.05. 
 
 
RESULTS 
 
Pharmacokinetic study 
In the present study, a new in situ-forming implant composed of BTM and safflower 
oil was evaluated for the sustained delivery of rivastigmine after s.c. injection. Table I 
lists all formulations which were administered for the pharmacokinetic study (PK 
group) and the exact doses that were actually given (target doses were 15 or 25 mg.kg-
1
 for the implants). In order to assess the extent of drug release, a threshold 
concentration of 1 ng.mL-1 was chosen as it corresponds to a level still providing 
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therapeutic benefits in humans [27]. Figure 2 shows the effect of the formulation 
composition (SAM vs. BTM gels) at 15 mg.kg-1 rivastigmine on the plasma levels as 
measured by LC/MS/MS. The control group received an oily dispersion of the drug at 
5 mg.kg-1. A higher dose was not injected due to strong side-effects such as high 
shaking, lifeless state and harderian porphyrin excretion, probably related to the high 
Cmax, the maximal value of the rivastigmine plasmatic concentration. In this 
experiment, the volume of formulation administered was 300 µL. As shown in Figure 
2 and Table II, the addition of SAM or BTM to safflower oil decreased substantially 
the burst release and provided sustained drug levels (> 1 ng mL-1) for ca. 10 days 
(compared to 2 days for the control PK-Oil-300-5). The Cmax was reduced by 5 and 10 
fold, respectively for a total drug dose which was 3 times higher than the control. 
BTM was twice more effective at reducing Cmax than SAM. However, the BTM 
formulation was not better at prolonging drug release. 
 
In the second experiment, the effects of the volume of implant and drug loading on 
the rivastigmine plasma levels were investigated using the BTM gel. The rats received 
25 mg.kg-1 rivastigmine by either raising the volume of the injected formulation from 
300 to 500 µL or by increasing the drug loading in the gel from ca. 1.5 to 2.5% while 
maintaining the injected volume to 300 µL. As illustrated in Figure 3, the 300-µL gel 
with the higher drug content provided sustained drug levels for 14 days and exhibited 
a 20% increase in Cmax and 40% increase in area under the plasma concentration vs. 
time curve (AUC) compared to the 15 mg.kg-1 dose (Table II). There was also a shift 
in tmax (time corresponding to Cmax) from 15 min to 8 h. As shown in Figure 3, the 
volume of the implant had a more pronounced impact of the pharmacokinetic profile 
than the drug content. Indeed, by raising the injected volume from 300 to 500 µL 
(PK-BTM-300-25 vs. PK-BTM-500-25), sustained plasma levels were achieved for 
more than 35 days. Interestingly, despite the fact that the total dose was increased 
from 15 to 25 mg.kg-1, the Cmax value did not change (397 vs. 334 ng.mL-1) (Table II). 
In this case also, the tmax shifted from 15 min to 8 h. 
 
AChE activity titration 
In a subsequent study, the pharmacological activity of the two BTM formulations 
presenting the lowest burst release (Table 1, ET-BTM-300-15 and ET-BTM-500-25 
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for a total drug dose of 15 and 25 mg.kg-1, respectively) was assessed in vivo and 
compared to that of a daily s.c. injection of a 1.5 mg.kg-1 rivastigmine saline solution 
(x 10 days for a total administered dose of 15 mg.kg-1). The animals were sacrificed at 
different time points and the AChE activity was assayed in the frontal, temporal and 
parietal cortices and the striatum (Supplementary Figures S1-S3) and hippocampus 
(Figure 4). Except for temporal and parietal cortices at day 7, the daily injection of 
rivastigmine solution was not able to significantly inhibit the activity of AChE in the 
analyzed sections of the brain (Supplementary Figure S1 and Figure 4). Moreover, 
rats receiving this control solution seemed to experience an initial increase of AChE 
activity both in the hippocampus (Figure 4) and in other brain structures studied here 
(Supplementary Figure S1) at day 3. Such an initial amplification could be explained 
by an autologous counterregulation of AChE levels. The injection of the rivastigmine 
solution and subsequent sudden exposure to high drug levels might have triggered 
AChE release from cerebral neurons stored to counterbalance the rivastigmine effect. 
Shapira et al. [31] and Kaufer et al. [32] already showed the possibility of an AChE 
accumulation in brain in response to anti-AChE intoxication and acute stress  
respectively. Such a trend was not observed in the implant-treated groups possibly 
because of the slower drug release. The ET-BTM-300-15 formulation decreased 
significantly the AChE activity in the frontal, temporal and parietal cortices and the 
striatum for the first 3 days (Supplementary Figure S2). After 7 days of rivastigmine 
release, AChE activity returned to the baseline level. In the striatum, some activity 
seemed to persist after 10 days, but due to the relatively important variability, 
statistical significance could not be established. For ET-BTM-500-25, the same trend 
was observed over a longer period of time (35 days for the striatum) but statistical 
significance could not be demonstrated after 10 days (Supplementary Figure S3). The 
most noticeable AChE inhibition was observed in the hippocampus. While the saline 
solution was ineffective, BTM implants were able to inhibit the AChE activity in a 
prolonged fashion (Figure 4). The ET-BTM-300-15 formulation produced a 20% 
inhibition of enzymatic activity 3 days after administration (p<0.05). Return to 
baseline levels occurred between days 3 and 7. The ET-BTM-500-25 system 
displayed more sustained enzymatic inhibition. The effect lasted up to 14 days with a 
significant difference, after which the AChE activity progressively returned to its 
initial level (Figure 4).  
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Biocompatibility study 
In the last part of the work, the biocompatibility of the BTM implants after s.c. 
injection was investigated. The impact of rivastigmine on the inflammatory reaction 
was measured (Table I, BC study) and the data were compared to a negative control 
and to the inflammatory reaction produced by a commercial formulation of an in situ 
forming implant composed of PLGA and NMP (Eligard®) (Figures 5 and 6). At the 
macroscopic level, the injection of the drug-free and rivastigmine loaded BTM 
organogels did not cause any redness of swelling (data not shown). Likewise, during 
the whole study period animals did not show external signs of side-effects such as 
weight loss or loss of appetite. The histological analysis of the injection site revealed 
that subcutaneous tissues presented a granulomatous chronic inflammatory reaction as 
for foreign body, accompanied by cicatricial-aspect fibrosis near the organogel 
implant (Figure 5B). The inflammatory reaction to the formulation was rivastigmine-
independent. In addition to fibrosis (Figure 5D), the lesions included inflammatory 
infiltrates with epitheloid cells, macrophages, multi-nucleus giant cells, and 
lymphocytes around the cholesteronilic cleft (Figure 5C). No difference in fibrosis 
and chronic inflammatory infiltration was observed between BC-BTM-500-0 and BC-
BTM-500-25. Compared to negative controls (no treatment for the animals), fibrosis 
increased slightly in intensity from minimal to minimal-mild at some time points but 
did not exceed this level (Figure 6A). For both formulations, inflammatory chronic 
infiltrate rapidly increased until a mild-moderate level was reached at day 7 (Figure 
6B). Then, the inflammation decreased and the characteristic infiltrates returned to a 
minimal-mild level grade at day 14 and remained constant thereafter. Interestingly, 
organogels produced an inflammatory reaction that was comparable to that of 
Eligard®. The optical histological micrograph did not reveal any difference between 
both formulations (compare Figures 5E and 5F). The hypoderm reaction displayed the 
same evolution for both formulations after 30 and 70 days: a minimal-mild level of 
the inflammatory chronic infiltrate and fibrosis responses (Figure 6). 
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DISCUSSION 
 
Alzheimer’s disease is characterized, among other neuropathological features, by the 
degeneration of cholinergic neurons in the cortex and hippocampus, resulting in lower 
levels of acetylcholine and altered cholinergic transmission [33]. Barnes et al. showed 
that the overall hippocampal atrophy rate is 1.4% in healthy patients from 69 to 83 
years; this rate increased to 4.6% for subjects with Alzheimer’s disease [34]. 
Rivastigmine is a selective cholinesterase inhibitor. It links to the esteratic and ionic 
site of AChE, preventing the enzyme from metabolizing acetylcholine. This inhibition 
while generalized to all brain structures expressing the cholinergic phenotype is 
particularly relevant in regions associated with Alzheimer’s disease neuropathology 
such as the fronto-parietal cortex and the hippocampus. This is the basis for the use of 
AChE inhibitors in this disease [35], the role of the hippocampus in cognitive 
processes being well established [36,37]. 
 
Until 2007, AChE inhibitors were only available as oral formulations taken once or 
twice daily in order to achieve adequate and consistent inhibition of cholinesterase 
[33]. Recently, a once-a-day rivastigmine patch received approval in the US. The 
patch exhibited an efficacy similar to that of the oral dosage form with significantly 
less gastro-intestinal side effects [38] and was found more convenient for the 
caregiver [39]. Persistence to oral AChE inhibitors is reported to be poor [40] and the 
adherence to the treatment, although apparently good, requires a high level of 
intervention and including the use of pill boxes and assistance in taking prescribed 
drugs [41].  
 
Compared to oral formulations, injectable controlled-release dosage forms generally 
provide greater dosing precision, and lower inter-subject variability due to the absence 
of erratic absorption. Parenteral depot also reduce the large differences in peak and 
trough plasma levels, which ultimately prevents the side-effects associated with 
repeated rapid increases in concentrations [42]. The literature on parenteral sustained-
release dosage forms for AChE inhibitors is scarce. Yang et al. [43] demonstrated that 
PLGA microspheres could sustain tacrine delivery in vitro for several weeks. 
Recently, several studies reported the use of biodegradable microspheres to sustain 
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the delivery of huperzine A, a natural AChE inhibitor isolated from the Chinese herb 
Huperzia serrata and approved for human use in China [44,45]. In rat [44,46] and dog 
models [47], it was found that the s.c. injection of huperzine A-loaded microspheres 
provided therapeutic plasma drug levels for ca. 15 to 60 days, and inhibited the rat 
cerebral cortex AChE by 10 to 20%. More recently, PLGA microspheres were 
investigated for the s.c. delivery of donepezil, another marketed AChE inhibitor [48]. 
When injected at a single drug dose of 90 mg/kg, microspheres were found as 
efficient as an oral daily dose of 3 mg/kg/day during one month. 
 
In the present study, it was shown that optimized BTM gels could deliver rivastigmine 
for a period exceeding 4 weeks after s.c. administration. In order to facilitate the 
injection, the gels contained NMP at a NMP/BTM ratio of 3. This ratio was 
previously shown to fluidize the network while allowing the formation of 
reproducible gels after administration and diffusion of NMP in the surrounding 
environment [22]. Doses of 15 and 25 mg.kg-1 could be injected without inducing 
immediate visible side-effects. Conversely, injecting more than 5 mg.kg-1 of the 
control rivastigmine solution was associated with strong side effects (data not shown). 
In terms of burst release in vivo, this system was also proven superior to the SAM 
implant which was initially investigated [26] (Figure 2). Indeed, compared to L-
alanine gels, the L-tyrosine derivatives possess higher gel-sol phase transition 
temperatures and elastic moduli [22]. The superior gelling ability of tyrosine 
derivatives could be explained by their well-structured 2-dimensional packing in the 
network. Such a packing was found to possibly involve van der Waals interactions 
and H-bonds in one direction and H-bonds between the phenol heads in the other 
direction [22]. In vitro release kinetics showed that the burst release from L-alanine 
based gels was indeed higher than that of the L-tyrosine counterpart [22]. 
 
Increasing the volume of injected implants was efficient to prolong the in vivo release 
of rivastigmine plasma levels. Indeed, at 25 mg.kg-1, the 300-µL implant provided 
rivastigmine concentrations above 1 ng.mL-1 for 14 days whereas this threshold was 
reached after 35 days for the 500-µL system (Table II and Figure 3). Following the 
burst phase, it is thought that drug release is mostly driven by erosion and/or implant 
degradation by subcutaneous esterases and lipases [49,50]. The observed sustained 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
release was accompanied by a measurable pharmacological effect as demonstrated by 
the significant inhibition of AChE in the hippocampus (i.e. brain region involved in 
episodic memory [36,37]) for at least 14 days (Figure 4).  
 
The present study also demonstrated that the BTM implants either empty or loaded 
with rivastigmine were biocompatible after s.c. administration. Indeed, the 
inflammatory reaction observed for up to 70 days was minimal to mild and in general 
comparable to that triggered by the marketed 3-month release in situ-forming PLGA 
implant, Eligard®. These data are in agreement with a previous study, which showed 
that SAM organogels elicited an inflammatory response similar to PLGA 
microspheres [24,51]. In the case of SAM (5% w/w in safflower oil), the implant 
completely degraded in vivo after about 30 days, whereas the BTM implants at the 
same organogelator concentration partly persisted for up to 70 days (data not shown). 
This greater in vivo persistence could be related to differences in the physical 
properties of these gels [22] but also in the degradation rates of organogelators. This 
point will have to be investigated in future studies. 
 
 
CONCLUSION 
 
This article reports the in vivo evaluation of an injectable sustained release 
formulation of rivastigmine, an AChE inhibitor. This implant was composed of BTM, 
safflower oil and the gelation inhibitor, NMP.  It formed in situ after the injection and 
was able to deliver rivastigmine for several weeks. The sustained rivastigmine 
concentrations in plasma were associated with the inhibition of AChE in various parts 
of the brain and in particular in the hippocampus, a structure well known to be 
affected early in the pathology of Alzheimer’s disease. The implant was well tolerated 
and therefore this approach could represent an alternative treatment for mild-to-
moderate Alzheimer’s disease in patients who are not compliant to a daily therapy. 
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Table I. The formulations for the pharmacokinetic (PK), enzymatic titration (ET) and 
biocompatibility (BC) studies.   
 
Study Formulation Organogelator Corg
a
 
(% w/w) 
Implant 
volume 
(µL) 
CRivb 
(% w/w) 
Rivastigmine 
dose (mg.kg-1) 
PK-Oil-300-5 --- 0 300 0.6 ± 0.1 5.9 ± 1.0 
PK-BTM-300-15 BTM 5 300 1.6 ± 0.4 14.9 ± 0.7 
PK-BTM-300-25 BTM 5 300 2.8 ± 0.3 25.9 ± 2.9 
PK-BTM-500-25 BTM 5 500 1.4 ± 0.2 21.8 ± 3.2 
PK 
PK-SAM-300-15 SAM 5 300 1.4 ± 0.2 13.2 ± 2.3 
ET-saline-1.5 --- 0 1000 0.045 c 15 d 
ET-BTM-300-15 BTM 5 300 1.8 ± 0.1 14.9 ± 1.8 ET 
ET-BTM-500-25  BTM 5 500 2.2 ± 0.9 26.8 ± 3.6 
BC-BTM-500-0 BTM 5 500 0 0 BC BC-BTM-500-25 BTM 5 500 1.7 ± 0.1 22.9 ± 3.0 
a – Organogelator concentration in safflower oil (%w/w); 
b – Rivastigmine concentration in safflower oil (%w/w); 
c – 0.045% (w/v) rivastigmine dissolved in 1 mL saline; 
d – Final dose given to rats after 10 days. 
 
Table
2 
 
 
 
 
Table II. Pharmacokinetic parameters of the different formulations injected to rats 
(n=8). Cmax is the maximal value of the rivastigmine plasmatic concentration and tmax 
the corresponding time. t1ng corresponds to the time when the rivastigmine 
concentration was less than 1 ng.mL-1. AUC corresponds to the area under the plasma 
concentration vs. time curve between days 0 and the last day of the study.   
 
Formulation Cmax (ng.mL-1) 
tmax  
(h) 
t1ng  
(day) 
AUC ± SD 
(h.ng.mL-1) 
PK-Oil-300-5 4077 0.25 2 4100 ± 1900 
PK-BTM-300-15 397 0.25 9 8100 ± 6600 
PK-BTM-300-25 482 8 14 11,600 ± 10,100 
PK-BTM-500-25 334 8 > 35 14,700 ± 7000 
PK-SAM-300-15 758 12 11 20,300 ± 17,600 
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Figure captions 
 
Figure 1.  
Schematic representation of the experimental design: implant preparation, formation 
and biodegradation, and in vivo experiments.  
 
Figure 2.  
Pharmacokinetic study (plasmatic rivastigmine concentration CRiv vs. time) of the 
following formulations: PK-Oil-300-5 (), PK-BTM-300-15 () and PK-SAM-300-
15 () (Mean ± SEM, n=8). Inset represents the early time points. 
 
Figure 3.  
Pharmacokinetic study (plasmatic rivastigmine concentration CRiv vs. time) of the 
following formulations: PK-BTM-300-25 () and PK-BTM-500-25 () (Mean ± 
SEM, n=8). Inset represents the early time points.  
 
Figure 4 
%AChE activity (AChE activity after x days / AChE activity for healthy rat at day 0) 
(Mean ± SD, n=8) in hippocampus at day 0 (  ) and after 3 (  ), 7 (  ), 10     
(  ), 14 (  ), 21 (  ), 28 (  ) and 35 days (  ). Rats received daily 
subcutaneous injections of ET-saline-1.5, and two organogel formulation injections 
(at day 0): ET-BTM-300-15 and ET-BTM-500-25. (*) p<0.05. 
 
Figure 5.   
Microscopic section of (A) normal skin and (B) subcutaneous tissue 7 days after 
injection of BC-BTM-500-25 with chronic inflammation (white arrow) and fibrosis 
(red arrow) in the vicinity of the implant (black arrow). (C) Higher magnification of 
the inflammatory infiltrate displayed in (B). The inflammatory cells consist of 
lymphocytes, macrophages (black rectangle) and multinucleated giant cells (yellow 
arrow). Cholesterol clefts are also observed focally (grey arrow). (D) Fibrosis 
typically surrounds the implant site and the inflammatory area for subcutaneous tissue 
7 days after injection of BC-BTM-500-25. (E) Subcutaneous tissue 70 days after 
injection of Eligard® (22.5 mg, 3 months) formulation. (F) Subcutaneous tissue 70 
days after injection of BC-BTM-500-25 formulation. 
 
Figure 6. 
Hypoderm lesions evaluation: (A) fibrosis and (B) chronic inflammatory infiltrate, 
graded from absent to severe, after subcutaneous injection of BC-BTM-500-0, BC-
BTM-500-25 and Eligard® (22.5 mg, 3 months) formulations after 7 (  ), 14           
(  ), 30 (  ) and 70 days (  ). The negative control (  ) corresponds to 
non treated rats. (Mean ± SD, n=3). 
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Figure S1. %AChE activity (AChE activity after x days / AChE activity for healthy rat at day 
0) (Mean ± SD, n=8) in various brain structures: frontal, temporal and parietal cortices, and 
striatum at day 0 ( ) and after 3 ( ) , 7 ( ) and 10 days ( ). Rats received daily 
subcutaneous injections of ET-saline-1.5 during ten days. (*) p<0.05. 
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Figure S2. %AChE activity (AChE activity after x days / AChE activity for healthy rat at day 
0) (Mean ± SD, n=8) in various brain structures: frontal, temporal and parietal cortices, and 
striatum at day 0 ( ) and after 3 ( ), 7 ( ), 10 ( ) and 14 days ( ). Rats received 
ET-BTM-300-15 formulation injections at day 0. (*) p<0.05. 
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Figure S3. %AChE activity (AChE activity after x days / AChE activity for healthy rat at day 
0) (Mean ± SD, n=8) in various brain structures: frontal, temporal and parietal cortices, and 
striatum at day 0 ( ) and after 3 ( ), 7 ( ), 10 ( ), 14 ( ), 21 ( ), 28 ( ) and 
35 days ( ). Rats received ET-BTM-500-25 formulation injections at day 0. (*) p<0.05. 
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